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Abstract
Objective: To determine the percentage of patients given standard 
doses of piperacillin/tazobactam or meropenem by continuous infusion 
who achieved the target pharmacokinetic/pharmacodynamic (PK/PD) in-
dex, which was defined as free concentrations four times more than the 
minimum inhibitory concentration (CMI) for 100% of the dosing interval 
(100% fT≥ 4 x MIC).
Method: Preliminary data from a larger prospective clinical study analy-
sing the PK/PD behaviour of β-lactams antibiotics continuous infusion (CI) 
in critical patients. The study was conducted in the intensive care units of 
a tertiary university hospital for adults ( June 2015-May 2017). Inclusion 
criteria: normal renal function (glomerular renal function (GFR) CKD-EPI for-
mula ≥ 60 mL/min/1.73 m2) and treatment with standard dose β-lactams 
CI. Concentrations at steady state (Css) conditions were determined using 
UHPLC-MS/MS. We selected the highest susceptible MIC for all likely 
organisms according to European Commitee on Antimicrobial Susceptibi-
lity Testing’s (i.e. piperacillin/tazobactam: 8 mg/L for enterobacteriaceae 
and 16 mg/L for Pseudomonas aeruginosa; meropenem: 2 mg/L for any 
Resumen
Objetivo: Determinar el porcentaje de pacientes, a los que se les admi-
nistró dosis estándar de piperacilina/tazobactam o meropenem en per-
fusión continua, que alcanzaban el índice farmacocinético/farmacodiná-
mico diana definido como el 100% del intervalo de administración en 
que las concentraciones de antibiótico libre fueron cuatro veces iguales o 
superiores a la concentración mínima inhibitoria (100% fT ≥ 4 x CMI).
Método: Datos preliminares obtenidos de un estudio clínico prospecti-
vo que analiza el comportamiento farmacocinético/farmacodinámico de 
los antibióticos betalactámicos administrados en perfusión continua en 
pacientes críticos. Se realizó en unidades de cuidados intensivos de un 
hospital universitario de tercer nivel, desde junio de 2015 a mayo de 
2017. Criterios de inclusión: adultos con función renal correcta (filtrado 
glomerular según la fórmula CKD-EPI ≥ 60 ml/min/1,73  m2) y tratados 
con dosis estándar de antibióticos betalactámicos en perfusión continua. 
Las concentraciones en estado de equilibrio estacionario fueron deter-
minadas mediante cromatografía líquida acoplada a espectrometría de 
masas (UHPLC-MS/MS). Se utilizaron valores de concentración mínima 
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Introduction
Sepsis is one of the main causes of mortality in intensive care units (ICU) 
and affects 19 million patients worldwide1. To reduce mortality and morbi-
dity2 due to sepsis, the rapid and early start of suitable antibiotic therapy 
within the first hour of a diagnosis of sepsis or septic shock is crucial. Howe-
ver, the best therapeutic approach for each patient is determined by his or 
her particular pathophysiology3. 
The class of antibiotics most commonly used in ICUs are β-lactams 
(BLAs), which include penicillins, cephalosporins, and carbapenems. BLAs 
are particularly used to combat gram-negative infections. The Spanish Na-
tional Study of the Surveillance of Nosocomial Infections in Intensive Care 
Medicine (ENVIN-HELICS) recently published its results on the development 
of nosocomial infections in 205 Spanish ICUs. This report confirmed the pre-
valence of gram-negative bacteria (GNB) and found that Escherichia coli 
(13%), Pseudomonas aeruginosa (13%), and Klebsiella pneumoniae (11%) 
were the most frequent GNBs in ICUs4. 
BLAs are time-dependent antibiotics5 and their pharmacokinetic/phar-
macodynamic (PK/PD) index for bactericidal efficiency is determined by 
the dosing interval percentage at which the free drug concentration (fCss) is 
kept above the minimum inhibitory concentration (MIC) of the microorganism 
or suspected microorganism causing the infection (%fT> MIC)6. 
However, controversy remains on the optimal dosing interval percen-
tage and how high the fCss should be above the MIC (i.e. fCss/MIC 
ratio)3. Initially, the %fT> MIC was established at 50% for penicillins and 40% 
for carbapenemics3. However, it has been argued that the target PK/PD 
index should be stricter in critical patients, and therefore, the fCss should 
be higher than the MIC over the entire (i.e. 100%) dosing interval. Other 
authors have proposed that the fCss should be up to four times higher 
than the MIC during the entire administration interval (100% fT≥ 4 x MIC), thus 
ensuring bactericidal activity and minimizing the emergence of antibiotic 
resistance7,8. 
Although intermittent infusion (IIn) is the most widely used antibiotic ad-
ministration method, its use could make it more difficult to attain the target 
PK/PD index9. Intermittent infusion necessarily entails plasma concentration 
fluctuations, which may lead to insufficient concentrations10. This risk is hig-
her in critically ill patients, who normally have PK alterations (i.e. patients 
with increased renal function may have increased volume of distribution and 
drug clearance) and are at an increased risk of infection by microorganisms 
with high MICs11. Previous studies have proposed that continuous infusion 
(CI) may be a better alternative to IIn, because CI may ensure steady state 
concentrations (Css) above the MIC for longer periods, thus providing better 
clinical outcomes12-14.
This proposal supports the hypothesis that CI would keep the fCss above 
the MIC as well as constant over the entire dosing interval, thus achieving 
improved clinical benefit. 
The main study aim was to determine the percentage of critical pa-
tients who would reach 100% fT≥ 4 MIC during CI with either piperacillin/
tazobactam (PTZ) or meropenem (MER). The secondary aims were as 
follows: 1) to determine the percentage of patients who would reach the 
less demanding PK/PD target of 100% fT≥ MIC; and 2) to assess possible 




A prospective PK study in adult patients admitted to the ICU of a 
tertiary hospital. The patients underwent empirical or targeted antibiotic 
treatment with BLAs due to suspected gram-negative infection. The BLAs 
under study were PTZ, MER, aztreonam, cefepime, and ceftazidime. This 
article only addresses PTZ and MER because these drugs were being 
used in more patients at the time of the interim analysis. The study is 
currently ongoing (i.e. in the recruitment, processing, and sample analysis 
phases). However, we present the preliminary results for the first 2 years 
( June 2015-May 2017). 
The study protocol was approved by the local Ethics Committee in ac-
cordance with the Declaration of Helsinki. Informed consent was requested 
from patients or family members before inclusion in the study. 
Study population
Inclusion criteria: i) patients admitted to the ICU; ii) treated with BLAs 
or able to receive them; iii) equal to or more than 18 years of age; 
and iv) preserved renal function defined as a glomerular filtration rate 
(GFR) ≥ 60 mL/min/1.73 m2 as estimated using the CKD-EPI equation15. 
Pregnant patients were excluded. 
Data collection
Demographic, clinical, and analytical data were obtained from the 
electronic registry of the hospital. We also collected pharmacological 
data on the antibiotic administered, dose, dosage, infusion time, and sam-
pling time. 
microorganism). In addition, a subanalysis of patients was conducted 
using actual MIC values.
Results: 61 patients were enrolled (25 to meropenem and 36 to pipe-
racillin/tazobactam). Average age was 59 (15) years and median GFR 
rate was 95 mL/min/1.73 m2 (83-115). Median meropenem and pipe-
racillin free concentrations were 16 mg/L (11-29) and 40 mg/L (21-51), 
respectively.
88% of patients treated with meropenem reached the PK/PD target, 
without differences between both microorganisms. For piperacillin/tazo-
bactam, 61% and 11% of patients reached the target, with enterobacteria-
ceae and Pseudomonas as suspected microorganisms, respectively. The 
pathogen was isolated in 35 (57%) patients: 94% reached the target PK/
PD, without differences between both antibiotic therapies. 
Conclusions: Standard doses of meropenem CI are sufficient to achieve 
a PK/PD target of 100% fT≥ 4 x MIC in suspected infections with high MICs 
(Pseudomonas aeruginosa or enterobacteriaceae). However, higher doses 
of piperacillin/tazobactam could be considered to achieve this goal. In 
patients with isolated microorganisms, a standard dose of both antibiotic 
therapies would be sufficient to achieve the target. Therapeutic drug moni-
toring is highly recommended for therapeutic optimization.
inhibitoria teóricos para microorganismos más resistentes (piperacilina/
tazobactam: 16  mg/l para Pseudomonas aeruginosa y 8  mg/l para 
Enterobacteriaceae; meropenem: 2  mg/l, independientemente del mi-
croorganismo). Además, se realizó un subanálisis de los pacientes con 
aislamiento microbiológico (concentraciones mínimas inhibitorias reales).
Resultados: Se incluyeron 61 pacientes (25 meropenem y 36 piperacili-
na/tazobactam). Edad media 59 años (15), mediana de filtrado glomerular 
95 ml/min/1,73 m2 (83-115). Mediana de concentraciones en estado de 
equilibrio estacionario  libre: 16 mg/l (11-29) meropenem y 40 mg/l (21-
51) piperacilina. El 88% de los pacientes tratados con meropenem alcan-
zaron el objetivo farmacocinético/farmacodinámico, sin diferencias entre 
Enterobacteriaceae y Pseudomonas. En el caso de piperacilina/tazobac-
tam, el 61% y el 11% de los pacientes alcanzaron la diana, considerando 
Enterobacteriaceae y Pseudomonas como microorganismo sospechoso. Un 
total de 35 (57%) pacientes presentaron aislamiento microbiológico. El 94% 
de ellos alcanzaron la diana, sin diferencias entre los dos antibióticos. 
Conclusiones: Ante la sospecha de infecciones por microorganismos 
con concentraciones mínimas inhibitorias elevadas (Pseudomonas aerugino-
sa o enterobacterias), se observa que dosis convencionales de meropenem 
en perfusión continua son suficientes para lograr la diana 100% fT≥ 4 x MIC. 
Sin embargo, se requerirían dosis superiores de piperacilina/tazobactam. 
En casos de aislamiento microbiológico, dosis estándar de ambos antibióti-
cos fueron suficientes para lograr la diana. La monitorización farmacocinéti-
ca es altamente recomendable para la optimización terapéutica.
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Dose and drug administration
Standard doses of antibiotics were administered by CI. The patients 
received a loading dose followed by the total daily dose by CI; those al-
ready treated by IIn for more than 24 hours could be changed to CI without 
the need of a loading dose, because Css had already been reached. PTZ 
infusions were changed every 24 hours (concentration: 80 mg/mL in 0.9% 
saline; stability: 24 hours at 25 °C)16; and MER infusions were changed 
every 12 hours (concentration: 22 mg/mL in 0.9% saline; stability: 17 hours 
at 25 °C)16. The protocolized maximum dose was 12 g/1.5 g/d for PIP/
tazobactam and 6 g/d for MER. 
Determination of plasma concentrations
Blood samples (5 mL) were taken 30 minutes after the loading dose 
or after at least four doses antibiotic IIn or 24 hours after starting CI (i.e. 
once the Css was reached). Total BLA concentrations were measured 
using a previously developed and validated UHPLC-MS/MS procedu-
re17. This procedure involved the precipitation of sample proteins with 
acetonitrile and subsequent dilution with water. The eluates obtained 
were then introduced into a C18 reverse phase column using a water/
acetonitrile gradient with formic acid. Finally, BLAs were detected using 
a triple quadrupole mass spectrometer set up for electrospray in po-
sitive ion (ESI+) mode and multiple reaction monitoring (MRM) mode. 
Retention times were 1.08 minutes for MER and 1.91 minutes for PIP. 
Processing time per sample was 3.5 minutes. The limits of quantification 
were 0.58 mg/L and 0.54 mg/L for PIP and MER, respectively. The 
coefficients of variation and relative bias absolute values were less than 
13.3% and 14.7%, respectively. 
The target PK/PD index 
The PK/PD index was calculated using the fCss/MIC ratio. The magni-
tude of the PK/PD index was the differentiating factor between the primary 
(100% fT≥ 4 x MIC) and secondary (100% fT≥ MIC) objectives. Only Css were 
analysed. We assumed 30% plasma protein binding for PIP18 and 2% for 
MER18. 
Based on the European Committee on Antimicrobial Susceptibility Tes-
ting (EUCAST)19, theoretical MIC values were used for the least sensitive 
bacteria: Pseudomonas aeruginosa (2 mg/L for MER and 16 mg/L for PTZ); 
and enterobacteriaceae (2 mg/L for MER and 8 mg/L for PTZ). We con-
ducted a subanalysis of patients with microbiological isolation using the 
Epsilometer test with actual MIC values. 
Statistical analysis
An anonymized database was used. The statistical analysis was per-
formed using the SPSS v.22.0 software package (SPSS Inc., Chicago, 
IL). The data and results are expressed as median (IQR), continuous 
variables are expressed as means (SD), and categorical variables are 
expressed as rates and percentages. The chi-square test was used to 
analyse differences between GFR groups in reaching the target PK/
PD index.
Results
Demographic and clinical data
A total of 77 patients were recruited. Sixteen patients were excluded 
due to nonadherence to the protocol: 12, due to missing samples to determi-
ne Css; 2, due to missing sampling time data, and 2, due to sample extrac-
tion errors. The final sample comprised 61 patients (25 MER and 36 PTZ). 
Table 1 shows the baseline characteristics of the patients.
PK/PD data
Although all the samples were analysed, fCss alone were used in this 
analysis. The median fCss was 16 mg/L (11-29) for MER and 40 mg/L 
(21-51) for PIP (see Figure 1). 
Primary objective (100% fT≥ 4 x MIC)
Assuming theoretical MIC values for all patients, 43% (P. aeruginosa) 
and 72% (enterobacteriaceae) of them would reach the target PK/PD in-
dex. Overall, microbiological isolation was achieved in 36 patients and 
the exact MIC was determined in 35. More than 90% of these patients 
reached the primary PK/PD target index (95% with PTZ and 94% with MER) 
(see Table 2).
Secondary objectives
Using either theoretical or real MIC values, more than 90% of patients 
would reach the PK/PD target of 100% fT≥ MIC (Table 2). No differences 
were detected between the GFR groups, although some patients with a GFR 
≥ 120 mL/min did not reach the PK/PD target index. Figure 2 shows the 
fCss/MIC ratio by GFR group. 
Figure 1. Free plasma concentrations of meropenem 















fCss: free plasma concentration at steady state; Q1, first quartile; Q3, third quartile.
003_11170_OTAC Optimización de la Terapia Antibiótica_ING.indd   153 28/8/19   12:14
154
Farmacia Hospi ta lar ia 2019l 
Vol. 43 l Nº 5 l 151 - 157 l Erika Esteve-Pitarch et al.
Table 1. Sociodemographic and clinical characteristics of the study population
All patients MER PTZ
Patients (n) 61 25 36
Sex Women [n (%)] 28 (46) 9 (36) 19 (53)
Men [n (%)] 33 (54) 16 (64) 17 (47)
Age [x (sd)] 59 (15) 59 (14) 58 (17)
Weight [x (sd)] 74 (15) 73 (14) 74 (16)
Height [x (sd)] 166 (8) 167 (7) 165 (9)
Renal function [Md (IQR)] 95 (83-115) 104 (77-119) 93 (85-110)
Reason for admission Surgery [n (%)] 20 (33) 9 (36) 11 (31)
Clinical [n (%)] 39 (64) 16 (64) 23 (64)
Multiple trauma [n (%)] 2 (3) 0 2 (5)
Type of infection Abdominal [n (%)] 5 (8,2) 4 (16) 1 (3)
Bacteraemia [n (%)] 7 (11,5) 2 (8) 5 (14)
Respiratory [n (%)] 45 (74) 17 (68) 28 (77)
CNS [n (%)] 2 (3) 1 (4) 1 (3)
Osteoarticular [n (%)] 2 (3) 1 (4) 1 (3)
Microbiology Klebsiella spp. [n (%)] 5 (8) 2 (8) 3 (8)
Acinetobacter spp. [n (%)] 1 (2) 1 (4) 0
Escherichia coli [n (%)] 6 (10) 5 (20) 1 (3)
Staphylococcus spp. [n (%)] 3 (5) 2 (8) 1 (3)
Pseudomonas aeruginosa [n (%)] 12 (20) 4 (16) 8 (22)
Streptococcus spp. [n (%)] 3 (5) 1 (4) 2 (6)
Enterococcus faecium [n (%)] 1 (2) 1 (4) 0
Hemophilus influenzae [n (%)] 2 (3) 0 2 (6)
Serratia marcescens [n (%)] 1 (2) 0 1 (3)
Fusobacterium spp. [n (%)] 1 (2) 0 1 (3)
Enterobacter aerogenes [n (%)] 1 (2) 0 1 (3)
No isolatio [n (%)] 25 (41) 9 (36) 16 (44)
MV [n (%)] 37 (61) 14 (56) 23 (64)
APACHE score at admission [x (sd)] 17 (9) 21 (11) 15 (5)
SOFA II score at admission [x (sd)] 6 (4) 7 (5) 5 (3)
APACHE: Acute Physiology and Chronic Health Evaluation; CNS: central nervous system; IQR: interquartile range; Md: median; MER: meropenem; MV: mechanical ventila-
tion; PTZ: piperacillin/tazobactam; sd: standard desviation; SOFA: Sequential Organ Failure Assessment; x: median.
Figura 2. fCss/MIC ratio at 100% of the dosing interval according to the antibiotic and the theoretical MIC value used: A) meropenem; B) piperacillin assuming a 
MIC value of 8 mg/L; and C) piperacillin assuming a MIC value of 16 mg/L. 

































































003_11170_OTAC Optimización de la Terapia Antibiótica_ING.indd   154 28/8/19   12:14
155
Farmacia Hospi ta lar ia 2019 
l Vol. 43 l Nº 5 l 151 - 157 lOTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion
Discussion
The present study confirmed the results reported by other authors9,20,21, 
who found that drug under-exposure in critically ill patients could be 
avoided by the administration of antibiotics by CI, which is a simple 
alternative to classic administration. Dulhunty et al.9 and Abdul-Aziz et 
al.20,21 studied patients receiving BLAs by IIn or CI and analysed di-
fferences in the PK/PD index between groups. Their patients and our 
patients had similar characteristics. Dulhunty et al. used the same doses 
of antibiotics as those used in the present study. They found that 82% of 
patients in the CI group reached Css above the MIC for P. aeruginosa 
(100% with MER and 75% with PIP)9. Abdul-Aziz et al. analysed expo-
sure after the administration of 18 g/d PTZ, 3 g/d MER, and 6 g/d 
cefepime. They found that 97% of the fCss in the CI group reached the 
target of 100% fT> MIC. It is noteworthy that the use of higher PTZ doses 
reached a median fCss of 4 MICs in 100% of patients, in contrast to 
the results obtained in our study. The differences in exposure obtained 
with PTZ and MER could be explained by differences between the me-
dian GFR in our study population (95 mL/min/1.73 m2) and that in the 
population (64 mL/min) studied by Abdul-Aziz et al.20. The results of the 
present study (43% patients reached fCss> 4 x MIC) were better than those 
obtained in another study by Abdul-Aziz et al.21, in which only 31% of 
the patients in the CI group reached this target. 
Regarding the debate on the fCss/MIC ratio and the dosing interval 
percentage3,7, some in vitro and animal model studies have suggested that 
Css should be maintained at four to five times above the MIC to achieve 
an acceptable cure rate using CI regimens. The majority of these studies 
were conducted using resistant GNB (MIC of 64 mg/L for ceftazidime)22. 
For this reason, the secondary objective addressed 100% of the dosing 
interval instead of the 40% to 50% described in previous studies3. It is 
commonly argued that the higher the dosing interval percentage with Css 
> MIC in critical patients, the higher the probability of survival (odds ratios, 
1.02 [95% CI, 1.01-1.04] for 50% fT> MIC and 1.56 [95% CI, 1.15-2.13] for 
100% fT> MIC)6. 
A potential limitation of this study was the use of the CKD-EPI formula to 
determine renal function. This method was used because it was impossible 
to conduct 8- to 24-hour urine collection to directly measure creatinine13,23. 
However, the CKD-EPI was considered to provide a more accurate calcu-
lation and prevent underestimation in those with GFR ≥ 60 mL/min15. One 
study24 has shown that patients with increased renal function are less likely 
to reach the target PK/PD index. In the present study, no statistical significan-
ce was observed in relation to PK/PD target attainment in patients with a 
high GFR, but this result could be explained by the small sample size. Future 
analyses will include more patients to obtain more robust results and to be 
able to compare them to those of previous studies.
In this study, two analyses were performed according to the MIC value. 
Given that in 50% of cases no microorganism was isolated, the main and 
secondary objectives were analysed assuming theoretical MICs based on 
the breakpoint provided by EUCAST. This aspect may be another limita-
tion, because it overestimated the number of patients who did not reach 
the target PK/PD index. Nevertheless, the estimation is representative of 
actual clinical settings, in which the MIC is rarely available at the time 
of antibiotic treatment. Pharmacokinetics are affected by another relevant 
factor, hypoalbuminemia, which is found in 40% of critical patients25. Since 
the percentage of free drug is responsible for the bactericidal effect, mea-
suring total plasma concentrations can lead to the under- or overestimation 
of the fCss. This situation applies to BLAs due to their high protein binding 
(more than 70% in ceftriaxone or ertapenem)26, but is not considered a 
limitation of MER or PIP, which have very low and moderate protein bin-
ding, respectively27. Nevertheless, to increase the accuracy of the results, 
unbound concentrations were also analysed. Finally, it should be noted that 
therapeutic ranges cannot be defined, because they depend on the MIC 
of the microorganism, the patient’s clinical/toxicity status, and pathophy-
siology, all of which may compromise drug exposure (i.e., high distribution 
volume or hyperfiltration)24,28. Given that there is no established range for 
these types of antibiotics, the concentration thresholds considered to be 
toxic were taken as the reference maximum values: 150 mg/L for PIP (fCss 
105 mg/L)29 and 64 mg/L for MER (fCss 62 mg/L)30.
More clinical trials are needed to establish therapeutic targets and as-
sess their clinical impact on critical patients. 
Conventional doses of MER by CI were sufficient to reach the two PK/
PD targets to treat suspected infections by microorganisms with high MICs, 
such as Pseudomonas aeruginosa or enterobacteriaceae, which are com-
mon in ICUs. Nevertheless, higher doses of PTZ were required to achieve 
a 100% fT≥ 4 x MIC. However, when microbiological isolation was achieved 
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MER: meropenem; PIP: piperacillin; MIC: minimum inhibitory concentration; GFR: glomerular filtration rate; fCss: plasma concentration of free drug at steady state.
*P value: chi-square. ¥The percentages of patients who reached the target in each GFR group were calculated using all the patients belonging to each GFR group. 
°Microorganisms are listed in table 1.
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(i.e. the MIC was known), standard doses of MER and PTZ were sufficient 
to obtain both target PK/PD indices. The present study found that in patients 
with elevated renal function there was a slight, but non significant, trend 
towards subtherapeutic concentrations. Pharmacotherapeutic monitoring is 
highly recommended to optimize treatment in critically ill patients.
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Contribution to the scientific literature 
We investigated the pharmacokinetic behaviour of continuous infu-
sion β-lactams in order to optimize this antibiotic therapy. Continuous 
infusion and monitoring plasma concentrations allows dosages to be 
individualized according to the clinical situation and the minimum inhi-
bitory concentration of the microorganism or suspected microorganism 
causing the infection. In this context, therapeutic drug monitoring can 
be useful to determine how the plasma concentration of the drug is 
affected by the pathophysiology of the critical patient. It may also be of 
help in clinical decision making. 
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PROA-OTAC Hospital Universitari de Bellvitge multidisciplinary group. 
Víctor Daniel Gumucio-Sanguino1, Anna Farré-Estebe1, Laura Anguela-Calvet1, Joan Sabater-Riera1, Xosé Pérez-Fernández1, Mariel Rojas-Lora1, Raúl Rigo-
Bonin2, Fe Tubau-Quintano3 y Evelyn Shaw-Perujo4. 
1Servicio de Medicina Intensiva, Hospital Universitario Bellvitge-IDIBELL, Hospitalet de Llobregat. Spain. 2Servicio de Bioquímica, Hospital Universitario 
Bellvitge-IDIBELL, Hospitalet de Llobregat. Spain. 3Servicio de Microbiología, Hospital Universitario Bellvitge, Hospitalet de Llobregat. Spain. 4Servicio de 
Enfermedades Infecciosas, Hospital Universitario Bellvitge-IDIBELL, Hospitalet de Llobregat. Spain.
Bibliography
1. Angus DC, Van der Poll T. Severe sepsis and septic shock. N Engl J Med. 
2013;369(9):840-51. DOI: 10.1056/NEJMra1208623
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving 
Sepsis Campaign: International Guidelines for Management of Sepsis and Septic 
Shock: 2016. Intensive Care Med. 2017;43(3):304-77. DOI: 10.1007/s00134-
017-4683-6
3. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. 
Individualised antibiotic dosing for patients who are critically ill: challenges and 
potential solutions. Lancet Infect Dis. 2014;14(6):498-509. DOI: 10.1016/S1473-
3099(14)70036-2
4. Grupo de trabajo de enfermedades infecciosas y sepsis. Estudio nacional de vigi-
lancia de infección nosocomial en servicios de medicina intensiva (EVIN-HELICS). 
Informe 2017 [monograph on Internet]. Barcelona, España: Sociedad Española 
de Medicina Intensiva y Unidades Coronarias (SEMICYUC); 2017 [accessed 
20/2/2018]. Available at: http://hws.vhebron.net/envin-helics/
5. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. 
Crit Care Med. 2009;37(3):840-51. DOI: 10.1097/CCM.0b013e3181961bff
6. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: 
Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Anti-
biotic Doses Sufficient for Critically Ill Patients? Clin Infect Dis. 2014;58(8):1072-83. 
DOI: 10.1093/cid/ciu027.
7. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, 
et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of 
concept. Int J Antimicrob Agents. 2010;36(4):332-9. DOI: 10.1016/j.ijantimi-
cag.2010.06.008
8. Delattre IK, Taccone FS, Jacobs F, Hites M, Dugernier T, Spapen H, et al. Optimi-
zing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmaco-
dynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther. 
2017;15(7):677-88. DOI: 10.1080/14787210.2017.1338139
9. Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, et al. 
Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Dou-
ble-Blind, Randomized Controlled Trial. Clin Infect Dis. 2013;56(2):236-44. DOI: 
10.1093/cid/cis856
10. Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-
lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 
2012;2(1):37. DOI: 10.1186/2110-5820-2-37
11. Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. Applying Phar-
macokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing 
Efficacy and Reducing Resistance Development. Semin Respir Crit Care Med. 
2015;36(1):136-53. DOI: 10.1055/s-0034-1398490
12. Rhodes NJ, Liu J, O’Donnell JN, Dulhunty JM, Abdul-Aziz MH, Berko PY, et al. Pro-
longed Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outco-
mes in Severely Ill Patients. Crit Care Med. 2018;46(2):236-43. DOI: 10.1097/
CCM.0000000000002836
13. Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ. Po-
pulation pharmacokinetics of continuous infusion of piperacillin in critically ill 
patients. Int J Antimicrob Agents. 2018;51(4):594-600. DOI: 10.1016/j.ijantimi-
cag.2017.12.015
14. Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, et al. Mode-
lled target attainment after meropenem infusion in patients with severe nosocomial 
pneumonia: The PROMESSE study. J Antimicrobial Chemother. 2015;70(1):207-16. 
DOI: 10.1093/jac/dku354
15. Florkowski CM, Chew-Harris JSC. Methods of Estimating GFR – Different equations 
including CKD-EPI. Clin Biochem Rev. 2011;32(2): 75-9.
16. IBM Watson Health. IBM Micromedex® web applications access [data base on Inter-
net]. Greenwood Village, Colorado, USA: ©Copyright IBM Corporation 1/6/1970 
[30/6/2019; 12/10/2018]. Available at: https://www.micromedexsolutions.com/
17. Rigo-Bonnin R, Ribera A, Arbiol-Roca A, Cobo-Sacristán S, Padullés A, Murillo Ò, 
et al. Development and validation of a measurement procedure based on ultra-high 
performance liquid chromatography-tandem mass spectrometry for simultaneous 
measurement of β-lactam antibiotic concentration in human plasma. Clin Chim 
Acta. 2017;468:215-24. DOI: 10.1016/j.cca.2017.03.009
18. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de 
información online de medicamentos (CIMA) de la AEMPS [data base on Inter-
net]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad 30/12/1997 
[15/4/2016; 20/7/2018]. Available at: https://www.aemps.gob.es/cima/ini-
cial.do
19. European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 
Clinical breakpoints-bacteria (v 9.0) [data base on Internet]. Sweden: The Euro-
pean Commitee on Antimicrobial Susceptibility Testing (EUCAST) 12/2/1983 
[1/1/2019; 20/2/2019]. Available at: http://www.eucast.org/clinical_break-
points/
20. Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, et al. Beta- 
Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled 
randomised controlled trial of continuous versus intermittent beta-lactam infusion in 
critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535-45. 
DOI: 10.1007/s00134-015-4188-0
21. Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, Waele JJ, Dimopoulos G, et al. Is 
prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients 
associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? 
003_11170_OTAC Optimización de la Terapia Antibiótica_ING.indd   156 28/8/19   12:14
157
Farmacia Hospi ta lar ia 2019 
l Vol. 43 l Nº 5 l 151 - 157 lOTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion
An observation from the Defining Antibiotic Levels in Intensive care unit patient (DALI) 
cohort. J Antimicrob Chemother. 2016;71:196-207. DOI: 10.1093/jac/dkv288
22. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during conti-
nuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. 
Antimicrob Agents Chemother. 1994;38: 931-6. 
23. Aardema H, Nannan Panday P, Wessels M, van Hateren K, Dieperink W, Koste-
rink JGW, et al. Target attainment with continuous dosing of piperacillin/tazobac-
tam in critical illness: a prospective observational study. Int J Antimicrob Agents. 
2017;50(1):68-73. DOI: 10.1016/j.ijantimicag.2017.02.020
24. Carrié C, Petit L, d’Houdain N, Sauvage N, Cottenceau V, Lafitte M, et al. Asso-
ciation between augmented renal clearance, antibiotic exposure and clinical outco-
me in critically ill septic patients receiving high doses of β-lactams administered 
by continuous infusion: a prospective observational study. Int J Antimicrob Agents. 
2018;51(39):443-9. DOI: 10.1016/j.ijantimicag.2017.11.013
25. Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, et al. An 
international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring 
practice in intensive care units. J Antimicrob Chemother. 2014;69(5):1416-23. DOI: 
10.1093/jac/dkt523 
26. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. Protein 
binding of β-lactam antibiotics in critically ill patients: can we successfully predict 
unbound concentrations? Antimicrob Agents Chemother. 2013;57(12):6165-70. 
DOI: 10.1128/AAC.00951-13
27. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of 
hypoalbuminaemia on optimizing antibacterial dosing in critically ill pa-
tients. Clin Pharmacokinet. 2011;50(2):99-110. DOI: 10.2165/11539220-
000000000-00000
28. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured 
and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473-83. 
DOI: 10.1056/NEJMra054415
29. Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, et al. Daily serum 
piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents. 
2010;35(5):500-3. DOI: 10.1016/j.ijantimicag.2010.01.018
30. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Me-
ropenem dosing in critically ill patients with sepsis and without renal dysfunction: 
intermittent bolus versus continuous administration? Monte Carlo dosing simulations 
and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142-50. 
DOI: 10.1093/jac/dkp139
003_11170_OTAC Optimización de la Terapia Antibiótica_ING.indd   157 28/8/19   12:14
